Cogent Biosciences (COGT)
(Real Time Quote from BATS)
$6.55 USD
+0.02 (0.31%)
Updated Apr 18, 2024 01:26 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
COGT 6.55 +0.02(0.31%)
Will COGT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for COGT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COGT
Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?
Cogent Biosciences, Inc. (COGT) Is a Great Choice for "Trend" Investors, Here's Why
COGT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 66% Upside in Cogent Biosciences, Inc. (COGT): Can the Stock Really Move This High?
Here's What Could Help Cogent Biosciences, Inc. (COGT) Maintain Its Recent Price Strength
Biotech Stock Roundup: BLUE Up on Regulatory Updates, RIGL's Pipeline News & More
Other News for COGT
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
Cogent Biosciences presents preclinical data of CNS-penetrant ErbB2 inhibitor
Commit To Buy Cogent Biosciences At $5, Earn 21.4% Annualized Using Options
Cogent Biosciences files to sell 31.2M shares of common stock for holders